In a case study of its so-called “drug of the year,” Trinity noted that argenx was able to successfully secure market-leader status for Vyvgart soon after its launch thanks to its “safer ...

Switching to IMVT-1402 extends the head starts Immunovant has already ceded to its rivals. Argenx won FDA approval for ...

Netherlands biotech Argenx has a second FDA approval for its FcRn inhibitor Vyvgart Hytrulo, adding a new indication in chronic inflammatory demyelinating polyneuropathy (CIDP) for a drug that it ...

These drugs work by blocking FcRn and impairing ... its core portfolio with the help of collaborative partners. The molecule in Vyvgart originated from a collaboration with UT Southwestern Medical ...

argenx SE (NASDAQ:ARGX) reported Q4 2024 results and provided a pipeline update today, but without major surprises since the company provided Vyvgart net sales and a corporate update ahead of the ...

The company has greatly expanded its global patient reach for Vyvgart to over 10,000 patients ... there is risk around its reliance on a single molecule for most of our 10-year forecast, which ...

"In 2024, we significantly expanded our global patient reach with VYVGART, surpassing 10,000 patients across three indications,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.

UCB also notes that unlike monoclonal antibody C5 inhibitors Zilbrysq is a smaller peptide molecule ... for Vyvgart Hytrulo (efgartigimod alfa), a subcutaneous FcRn blocker, in June. That drug ...